Health Professional Radio - Podcast

Dr. ​Steve Roman​o​, ​MD, ​Executive Vice President and Chief Scientific Officer at Mallinckrodt Pharmaceuticals discusses the results of their pivotal Phase 3 STRATA2016 clinical trial of StrataGraft ®, an investigational allogeneic cellularized scaffold product in development for the treatment of adult patients with deep partial-thickness burns. The data was published in "Burns" peer review journal (July 2021). It received FDA approval in July 2021 and can provide burn surgeons with an alternative biologic treatment option for patients with deep partial-thickness burns. #MallinckrodtPharmaceuticals #STRATA2016 Dr. Steven Romano is executive vice president and chief scientific officer at Mallinckrodt Pharmaceuticals. He has executive responsibility for research and development (R&D), medical affairs and regulatory affairs functions, and is a member of Mallinckrodt’s executive committee. A board-certified psychiatrist, Dr. Romano has more than 20 years of experience in the pharmaceutical industry. Prior t